HLA Demographics Study in Adults With Type 1 Diabetes
Part of paid clinical trials in San Francisco, California.
- Sponsor
- GentiBio, Inc
- Study ID
- NCT06860516
- Status
- Recruiting
Conditions
- Diabetes Mellitus, Type I
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- blood draw or cheek swab — OTHERa blood draw or cheek swab for testing of HLA-DRB1\*04:01
Study Details
This is a study to evaluate the HLA-DRB1\*04:01 genotype in adults that have been diagnosed with type 1 diabetes
Key Dates
- First listed
- Mar 6, 2025
- Start date
- Jun 6, 2025
- Status verified
- Apr 2026
- Primary completion
- Jan 30, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: all participantsaged ≥ 18 to ≤ 55 years recently (within 6 months of the study visit) diagnosed with T1D
Primary Outcome Measure
HLA DRB1*04:01 positive [ Time Frame: Day 1 ]
Central Contacts
- Kristin M Neff, MS85-732-75483
- Mark Bach, MD908-578-3634
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94158 | Stephen Gitelman, MD (PRINCIPAL_INVESTIGATOR) |
| University of Florida- Gainesville | Gainesville | Florida | 32610 | Michael Haller, MD (PRINCIPAL_INVESTIGATOR) |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | Jason Gaglia, MD (PRINCIPAL_INVESTIGATOR) |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Carol Levy, MD (PRINCIPAL_INVESTIGATOR) |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | Klara Klein, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
Related Studies
- Primary Care Pragmatic, Real World Experience for Automated Insulin DeliveryRecruiting · University of Colorado, Denver · Aurora, Colorado